Ratiopharm Gmbh

Maschinenfabrik Reinhausen Gmbh

Heparegenix Gmbh

C-A-I-R Biosciences Gmbh

Siemens Aktiengesellschaft

Gkss-Forschungszentrum Geesthacht Gmbh

Merckle Gmbh

Other

Teva Pharmaceuticals International Gmbh

Helmholtz-Zentrum Geesthacht Zentrum Fur Material Und Kustenforschung Gmbh

Albrecht, Wolfgang

Wolfgang Albrecht

Roland Selig

Stefan Laufer

Sebastian Rabe

Richard Guserle

Annemarie Maier

Christian Hammer

Jens Geier

Frank Lehmann

Werner Hartmann

Roman Renz

Andreas Stelzer

Joerg Teichmann

Andreas Lawall

Norbert Wenzel

Christian Kotz

Sebastian Rehkopf

Thomas Weigel

Roland Hilke

Sylvio Kosse

Klaus Hoepfl

Uwe Kaltenborn

Alfred Bieringer

Christian Pircher

Andreas Sachsenhauser

Andreas Stocker

Eduard Zerr

Anatoli Saveliev

Gerhard Baeuml

Karola Tollmann

Dieter Paul

Ludovic Coutable

Karola Lützow

Manfred Erdmann

Thomas Strof

Christian Hurm

Hans-Günter Striegel

Phillip Klövekorn

Bent Präfke

David Perez Palacios

Martin Hausmann

Philip Klövekorn

Bent Praefke

Judith Aronhime

Dieter Dohnal

Vinod Kumar Kansal

Silke Wrede

Brijnath P Chaurasia

Hans-Henning Lessmann-Mieske

Marina Ratkaj

Manoj Dalsingar Yadav

Josef Neumeyer

Julia Hrakovsky

Hans-Guenter Striegel

Thomas M Huber

Rolf Lauterwald

Rainer Frotscher

Philipp Merckle

Ramesh Matioram Gidwani

Thomas Kammermeier

Gunter Kloth

Naveen C Srivastav

Ralph Stefan

Konrad Raedlinger

Gertraud Koellner

Dirk Fischer

Channaveerayya Hiremath

Claudia Dobler

Claudia Lauer

Ramkaran Prajapati

Pavan V Kumar

Hans-Juergen Mika

Siva Rama Krishna Muppalla

Roman Safonov

Dirk Schenk

Ashish Tripathi

Silvio Kosse

Andreas Sachsenhausen

Simone Eichner

Christoph Heynen

Martin Jatta

Mario Rettschlag

Filiana Santoso

Hans-Gunter Striegel

Barbara Seifert

Thomas Groth

Lars-Ingemar Dahms

Michael Juchum

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK1 and MKK7. In formula (I), especially, Ris —NRSOR; either a) Rand Rare F and Rand Rare H; or b) R, Rand Rare independently halogen and Ris H; Ris substituted phenyl or pyrimidinyl.

3-benzoyl-1H-pyrrolo[2,3-b]pyridine derivatives as MKK4 inhibitors for treating liver diseases

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7. (I), wherein R, R, Rand Rare selected from: a) Rand Rare F and Rand Rare H; b) R, Rand Rare independently halogen and Ris H; c) RRand Rare independently halogen and Ris H; and d) RRand Rare independently halogen and Ris H.

Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Tricyclic mitogen-activated protein kinases kinase 4 (MKK4) inhibitor compounds useful for promoting liver regeneration or reducing hepatocyte death by selectively inhibiting MKK4 over protein kinases JNK and MKK7.

Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.

The present invention relates (i) to a process for the preparation of quinolin-2-yl-phenylamine derivatives of formula (I) without a metal catalyst, and (ii) to soluble mineral acid or sulfonic acid salts of (8-chloro-quinolin-2-yl)-(4-trifluoromethoxyphenyl)-amine.

Process for preparing quinolin-2-yl-phenylamine derivatives and their salts

The present invention relates to co-crystals of ibrutinib and a pharmaceutical composition comprising the same as well as a method of preparing the same.

Methods of preparing co-crystals of ibrutinib with carboxylic acids

The present invention relates to an adduct of palbociclib, a method of preparing the preparing the same, and a pharmaceutical composition comprising the same. More particularly, the invention provides a crystalline form of palbociclib, a method of preparing the same, as well as a pharmaceutical composition comprising the same. 

Crystalline form and acetic acid adducts of palbociclib

The present invention relates to co-crystals of ibrutinib, a pharmaceutical composition comprising the same as well as a method of preparing the same.

Co-crystals of ibrutinib with carboxylic acids

The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.

Solid state forms of sofosbuvir

The invention relates to a switching arrangement () with a pre-selector () for a power transformer () which has multiple windings (). The pre-selector is designed to optionally connect at least one first winding () to one of the two end contacts () of at least one second winding (). At least one first switch is arranged in the connection between the pre-selector () and the first winding (), thereby allowing the pre-selector to be switched in an arc-free manner and thus in a gas-free manner as well.

Switching system with preselector

The present invention relates to acid addition salts of ibrutinib, a pharmaceutical composition comprising the same as well as a method of preparing the same.

Acid addition salt of ibrutinib

The invention relates to a step switch, comprising a pre-selector and a fine selector. The invention is characterized in that the step switch has a connection () between the pre-selector and the fine selector (), at least one coupling switch () being arranged in said connection. A pre-selector can be switched in a largely gas-free manner by means of said switchable connection with the aid of the fine selector.

Growing community of inventors

Ulm, Germany

Wolfgang Albrecht